Patents by Inventor Kate Duggento

Kate Duggento has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240029850
    Abstract: Server-implementing methods include receiving a selection of records for patients from an external source coupled to the server, and vectorizing at least set of healthcare record items associated with the selected patients and other patients from the data source. At least one vector element may be determined from healthcare record items for each patient. Vectors may be formed from at least one of the healthcare record items and the separate vectors concatenated together to form final vectors for the patients. A similarity search may be performed using the final vectors to determine a group of similar patients from the vectorized patients of the system. Selected patients that are within a same dimensional space as a focal patient may be labelled in the batch and presented on computer display. Further, intake of patient data from non-medical record sources may be automated and facilitated through the use of a large language model.
    Type: Application
    Filed: July 21, 2023
    Publication date: January 25, 2024
    Inventors: Kate Duggento CORDELL, Jacob William JORGENSEN
  • Patent number: 7485651
    Abstract: Compounds and methods are provided for the alleviation or treatment of diseases or conditions in which modification of muscarinic m1 receptor activity has a beneficial effect. In the method, a therapeutically effective amount of a selective muscarinic m1 agonist compound is administered to a patient in need of such treatment.
    Type: Grant
    Filed: January 7, 2003
    Date of Patent: February 3, 2009
    Assignee: Acadia Pharmaceuticals, Inc.
    Inventors: Mark Brann, Terri Messier, Erika Currier, Kate Duggento, Tracy Spalding, Mikael Friberg, Niels Skjaerbaek
  • Publication number: 20080108618
    Abstract: Compounds and methods are provided for the alleviation or treatment of diseases or conditions in which modification of muscarinic m1 receptor activity has a beneficial effect. In the method, a therapeutically effective amount of a selective muscarinic m1 agonist compound is administered to a patient in need of such treatment.
    Type: Application
    Filed: October 31, 2007
    Publication date: May 8, 2008
    Inventors: Mark Brann, Terri Messier, Erika Currier, Kate Duggento, Tracy Spalding, Mikael Friberg, Niels Skjaerbaek
  • Publication number: 20030144285
    Abstract: Compounds and methods are provided for the alleviation or treatment of diseases or conditions in which modification of muscarinic m1 receptor activity has a beneficial effect. In the method, a therapeutically effective amount of a selective muscarinic m1 agonist compound is administered to a patient in need of such treatment.
    Type: Application
    Filed: January 7, 2003
    Publication date: July 31, 2003
    Inventors: Mark Brann, Terri Messier, Erika Currier, Kate Duggento, Tracy Spalding, Mikael Friberg, Niels Skjaerbaek
  • Patent number: 6528529
    Abstract: Compounds and methods are provided for the alleviation or treatment of diseases or conditions in which modification of muscarinic m1 receptor activity has a beneficial effect. In the method, a therapeutically effective amount of a selective muscarinic m1 agonist compound is administered to a patient in need of such treatment.
    Type: Grant
    Filed: July 16, 1999
    Date of Patent: March 4, 2003
    Assignee: Acadia Pharmaceuticals Inc.
    Inventors: Mark Brann, Terri Messier, Erika Currier, Kate Duggento, Tracy Spalding, Mikael Friberg, Niels Skjaerbaek